David-Erick Lafontant

Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study

Andrew Siderowf, Luis Concha‐Marambio, David-Erick Lafontant et al. · The Lancet Neurology · 2023 · 693 citations · Full text

Life Sciences, Neurology, Neuroscience +14

National Institutes of Health–Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities

Camillo Ricordi, Julia Goldstein, Appakalai N. Balamurugan et al. · Diabetes · 2016 · 197 citations · Full text

Pharmacy, Manufacturing Engineering, Surgery +17

Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease

Tanya Simuni, Brian Fiske, Kalpana Merchant et al. · JAMA Neurology · 2020 · 143 citations · Full text

Medicine, Neurology, Pharmacology +17

Improved Health-Related Quality of Life in a Phase 3 Islet Transplantation Trial in Type 1 Diabetes Complicated by Severe Hypoglycemia

Eric D. Foster, Nancy D. Bridges, Irene D. Feurer et al. · Diabetes Care · 2018 · 118 citations · Full text

Medicine, Endocrinology, Surgery +17

Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older

Michael C. Brumm, Kerri A. Pierz, David-Erick Lafontant et al. · Neurology · 2023 · 68 citations · Full text

Medicine, Geriatric Medicine, Neurology +17